Antitrust: Commission opens investigation into possible anticompetitive disparagement by Vifor Pharma of iron medicine* The European Commission has opened a formal antitrust investigation to assess whether Vifor Pharma has restricted competition by illegally disparaging its closest – and potentially only – competitor in Europe on the market for intravenous iron treatment, Pharmacosmos. Vifor Pharma's conduct appears to be aimed at hindering competition against its blockbuster high-dose intravenous iron treatment medicine, Ferinject. Executive Vice-President Margrethe Vestager, in charge of competition policy, said: “Competition in the pharmaceutical sector is important. It provides access to
Share on
|
|
The EU Commission opens an investigation into possible anticompetitive disparagement between two pharmaceutical companies (Vifor Pharma / Pharmacosmos)
Access to this article is restricted to subscribers
Already Subscribed? Sign-in
Access to this article is restricted to subscribers.
Read one article for free
Sign-up to read this article for free and discover our services.
